HVJ liposomes and HVJ envelope vectors

Cold Spring Harbor Protocols

Volumn 6, Issue 10, 2011, Pages 1281-1289

  Kaneda, Yasufumi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; HJV ENVELOPE VECTOR; HJV LIPOSOME; LIPOSOME; OLIGONUCLEOTIDE; PEPTIDE; PLASMID DNA; PROTEIN; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL CULTURE; CYTOPLASM; DEGRADATION; GENE CONSTRUCT; GENE TARGETING; GENE THERAPY; HEARING IMPAIRMENT; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LIVER CIRRHOSIS; NEOPLASM; NONHUMAN; ORGAN CULTURE; PARAINFLUENZA VIRUS 1; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SENDAI VIRUS; VIRUS INACTIVATION; ANIMAL; CHICK EMBRYO; GENE VECTOR; GENETICS;

ANIMALIA; SENDAI VIRUS;

ANIMALS; CHICK EMBRYO; GENETIC VECTORS; LIPOSOMES; SENDAI VIRUS;

EID: 80053591935     PISSN: None     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.prot065748     Document Type: Article

References (34)

1. Asada M, Ohmi K, Delia D, Enosawa S, Suzuki S, Yuo A, Suzuki H, Mizutani S. 2004. Brap2 functions as a cytoplasmic retention protein for p21 during monocyte differentiation. Mol Cell Biol 24: 8236-8243.
2. Asano K, Asano A. 1988. Binding of cholesterol and inhibitory peptide derivatives with the fusogenic hydrophobic sequence of F-glycoprotein of HVJ (Sendai virus): Possible implication in the fusion reaction. Biochemistry 27: 1321-1329.
3. Chander R, Schreier H. 1992. Artificial viral envelopes containing recombinant human immunodeficiency virus (HIV) gp160. Life Sci 50: 481-489.
4. Dzau VJ, Mann M, Morishita R, Kaneda Y. 1996. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci 93: 11421-11425.
5. Goyal K, Huang L. 1995. Gene therapy using DC-Chol liposomes. J Liposome Res 5: 49-59.
6. Hirano T, Fujimoto J, Ueki T, Yamamoto H, Iwasaki T, Morishita R, Sawa Y, Kaneda Y, Takahashi H, Okada E. 1998. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Ther 5: 459-464.
7. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. 1993. Glomerulosclerosis induced by in vivo transfection with TGF-β or PDGF gene into rat kidney. J Clin Invest 92: 2597-2601.
8. Ito Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, et al. 2003. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 422: 173-176.
9. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. 2005. Rad51 siRNA delivered by HVJ envelope vector enhances the anticancer effect of cisplatin. J Gene Med 7: 1044-1052.
10. Kaneda Y, Iwai K, Uchida T. 1989a. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 243: 375-378.
11. Kaneda Y, Iwai K, Uchida T. 1989b. Introduction and expression of the human insulin gene in adult rat liver. J Biol Chem 264: 12126-12129.
12. Kaneda Y, Saeki Y, Morishita R. 1999. Gene therapy using HVJ-liposomes: The best of both worlds? Mol Med Today 5: 298-303.
13. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H. 2002. HVJ (hemagglutinating virus of Japan) envelope vector as a versatile gene delivery system. Mol Ther 6: 219-226.
14. Kato K, Nakanishi M, Kaneda Y, Uchida T, Okada Y. 1991. Expression of hepatitis B virus surface antigen in adult rat liver. J Biol Chem 266: 3361-3364.
15. Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K, Nakazawa S, Hirai H, Ozawa K, Inaba T. 2004. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 24: 6172-6183.
16. Mabuchi E, Shimizu K, Miyao Y, Kaneda Y, Kishima H, Tamura M, Ikenaka K, Hayakawa T. 1997. Gene delivery by HVJ-liposome in the experimental gene therapy of murine glioma. Gene Ther 4: 768-772.
17. Mima H, Tomoshige R, Kanamori T, Tabata Y, Yamamoto S, Ito S, Tamai K, Kaneda Y. 2005. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med 7: 888-897.
18. Miyata T, Yamamoto S, Sakamoto K, Morishita R, Kaneda Y. 2001. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumorspecific vector, HVJ-cationic liposomes. Cancer Gene Ther 8: 852-860.
19. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. 1993. Novel and effective gene transfer technique for study of vascular renin angiotensin system. J Clin Invest 91: 2580-2585.
20. Nakamura N, Hart DA, Frank CB, Marchuk LL, Shrive NG, Ota N, Taira T, Yoshikawa H, Kaneda Y. 2001. Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition. J Biochem 129: 755-759.
21. Nakamura H, Kimura T, Ikegami H, Ogita K, Kohyama S, Shimoya K, Tsujie T, Koyama M, Kaneda Y, Murata Y. 2003. Highly efficient and minimally invasive in vivo gene transfer to the mouse uterus by hemagglutinating virus of Japan (HVJ) envelope vector. Mol Hum Reprod 9: 603-609.
22. Nakanishi M, Uchida T, Sugawa H, Ishiura M, Okada Y. 1985. Efficient introduction of liposomes into cells using HVJ (Sendai virus). Exp Cell Res 159: 399-409.
23. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka S, Dang NH, Morimoto C. 2004. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci 101: 14186-14191.
24. Okada Y. 1993. Sendai-virus induced cell fusion. Methods Enzymol 221: 18-41.
25. Oshima K, Shimamura M, Mizuno S, Tamai K, Doi K, Morishita R, Nakamura T, Kubo T, Kaneda Y. 2004. Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats. FASEB J 18: 212-214.
26. Otomo T, Yamamoto S, Morishita R, Kaneda Y. 2001. EBV replicon vector system enhances transgene expression in vivo: Applications to gene therapy for cancer. J Gene Med 3: 345-352.
27. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. 1997. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 8: 2133-2141.
28. Shimamura M, Sato N, Oshima K, Aoki M, Kurinami H, Waguri S, Uchiyama Y, Ogihara T, Kaneda Y, Morishita R. 2004. A novel therapeutic strategy to treat brain ischemia: Over-expression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model. Circulation 109: 424-431.
29. Tomita N, Higaki J, Morishita R, Kato K, Kaneda Y, Ogihara T. 1992. Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 186: 129-134.
30. Tomita N, Morishita R, Yamamoto K, Higaki J, Dzau VJ, Ogihara T, Kaneda Y. 2002. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med 4: 527-535.
31. Tsuboniwa N, Morishita R, Hirano T, Fujimoto J, Furukawa S, Kikumori M, Okuyama A, Kaneda Y. 2001. Safety evaluation of HVJ-AVE liposomes in nonhuman primates. Hum Gene Ther 12: 469-487.
32. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, et al. 1999. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5: 226-230.
33. Yamamoto S, Yamano T, Tanaka M, Hoon DSB, Takao S, Morishita R, Aikou T, Kaneda Y. 2003. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther 10: 179-186.
34. Yamano T, Ura K, Morishita R, Nakajima H, Monden M, Kaneda Y. 2000. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 1: 574-580.